Starting Materials

Arranta Bio has partnered to offer select starting material process development and manufacturing services from dedicated laboratories and cGMP suites. This offers access to platform processes and analytical capabilities and technical expertise that allow you to move quickly from research to clinical trials.

Capabilities include:

  • Strain selection
  • Colony isolation and RCB generation
  • Platform production, purification, and linearization processes
  • Process transfer and optimization
  • Research and clinical-grade production

cGMP plasmid manufacturing services

Thermo Fisher Scientific has partnered with Arranta Bio to offer plasmid manufacturing services to advanced therapy innovators.

Together we offer the cGMP capacity, manufacturing processes, analytical capabilities, and technical expertise that allows you to move quickly from research to clinical trials to the commercial market. Rely on our teams’ manufacturing experience to ensure commercial-quality GMP plasmid DNA for advanced therapies right from the start—avoiding transitions in material quality and saving manufacturing time.

Click Here to Learn More about our capabilities:


Arranta Bio has dedicated process development laboratories with appropriate scale-down equipment for mRNA process establishment and development, including:

  • Plasmid linearization
  • Transcription reaction/mRNA synthesis
  • Enzymatic capping and tailing
  • DNA digestion
  • RNA purification including capture or other chromatography—product or process impurity removal studies, binding capacity, loading/elution buffer studies, elution/fraction collections studies, etc.
  • buffer exchange and/or concentration including filter configuration, flow rate, TMP, diafiltration volume, and loading studies
  • Process transfer and optimization
  • Non-cGMP mRNA production
  • Freeze-thaw and forced degradation stability studies

mRNA Lipid Nanoparticles

Our process development laboratories include dedicated space for establishing, developing and/or optimizing mRNA encapsulation and lipid nanoparticle formation and final formulation steps, including:

  • Solvent-based lipid emulsification
  • Lipid nanoparticle mRNA encapsulation— mixing technology platforms including microfluidics, T-junction mixing, and jet mixing
  • Chromatographic or filtration based polishing or final formulation steps including process and product impurity removal, dilution, concentration and buffer exchange step optimization
  • Non-cGMP LNP production
  • Freeze-thaw and forced degradation stability studies


We can accommodate non-cGMP, small-scale filling in our process development laboratories for drug product process establishment work or for non-clinical material production needs:

  • Sterile filtration studies
  • Container closure system evaluation
  • Non-cGMP production
  • Non-cGMP stability and forced degradation studies

Let’s Discuss Your Needs

Learn More